Nuvation Bio (NUVB) is addressing unmet medical need in cancer with lead approved drug Ibtrozi for ROS1 cancer, and clinical testing of Safusidenib for low and high grade glioma. The company released third quarter financial results today, and continues serving new patients with lead drug Ibtrozi, since being FDA approved for ROS1 NSCLC since June of 2025. Some key highlights from the second quarter results below.
- $45 million in third quarter, total revenue
- $27.5 Ibtrozi revenue
- 18% quarter over quarter Ibtrozi revenue growth
- License and collaboration revenue of $17 million
- Cash equivalents of $633 million
- Current Market cap of $1.5B
- Shares outstanding 352M
Third quarter displayed a slowing quarter over quarter Ibtrozi revenue growth of 18% versus the second quarter of 25.3% quarter / quarter growth. Second drug Safusidenib is currently in clinical trials for low and high grade glioma, with potential updates occurring mid year 2027. Nuvation is a speculative higher risk, long-term investment in the cancer space. Below is quarterly Ibtrozi revenue reported, and an estimated fourth quarter 25% growth revenue, yet to be reported. Thank you for reading.
Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.
